Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection

References

• Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm – volume 2. J Viral Hepatitis. 2015;22(Suppl 1):26–45.
   PubMed Web of Science ®Google Scholar
• Thein H-H, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418–431.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide – filling the gaps. J Viral Hepatitis. 2015;22(Suppl1):1–5.
   Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593.
   PubMed Web of Science ®Google Scholar
• Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008;28:397–404.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs. 2013;18:461–475.
   PubMed Web of Science ®Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59:434–441.
   PubMed Web of Science ®Google Scholar
• Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV – myth or foreseeable future? Liver Int. 2014;34:6–11.
   PubMed Web of Science ®Google Scholar
• Jaroszewicz J, Flisiak-Jackiewicz M, Lebensztejn D, et al. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opin Investig Drugs. 2015;24:1229–1239.
   PubMed Web of Science ®Google Scholar
• Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149:1462–1470.
   PubMed Web of Science ®Google Scholar
• Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs. 2015;75:675–685.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
   PubMed Web of Science ®Google Scholar
• Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:818–826.
   PubMed Web of Science ®Google Scholar
• Poordad F, Felizarta F, Asatryan A, et al. 100% SVR4 in HCV genotype 1 non-cirrhotic treatment-naïve or -experienced patients with the combination of ABT-493 and ABT-530 for 8 Weeks (SURVEYOR-I) (Abstract). Hepatology. 2015;62(Suppl 1):LB–14.
   Google Scholar
• Pilot-Matias T, Tripathi R, Cohen D, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59:988–997.
   PubMed Web of Science ®Google Scholar
• Krishnan P, Beyer J, Mistry N, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979–987.
   PubMed Web of Science ®Google Scholar
• Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445–5454.
   PubMed Web of Science ®Google Scholar
• Kati W, Koev G, Irvin M, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015;59:1505–1511.
   PubMed Web of Science ®Google Scholar
• Menon RM, Klein CE, Lawal AA, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir (Abstract 57). HEP DART; 2009 Dec 6–10; Hawaii, USA.
   Google Scholar
• Dumas E, Lawal A, Menon R, et al. Pharmacokinetics, safety and tolerability of the HCV NS5A inhibitor ABT-267 following single and multiple doses in healthy adult volunteers. J Hepatol. 2011;54(Suppl 1):S475–6.
   Google Scholar
• Menon R, Cohen D, Nada A, et al. Pharmacokinetics and tolerability of the HCV polymerase inhibitor ABT-333 following single ascending doses in healthy adult volunteers. J Hepatol. 2009;50(Suppl 1):S347–348.
   Google Scholar
• ClinicalTrials.gov. NCT01563536. Study to assess the safety, tolerability, pharmacokinetics and antiviral activity of ABT-267 in HCV infected subjects 2012. [ cited 2015 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT01563536.
   Google Scholar
• European Medicines Agency (EMA). Committee for medicinal products for human use (CHMP) assessment report. Exviera. International non-proprietary name: dasabuvir. Procedure No. EMEA/H/C/003837/0000. [ cited 2016 Mar 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003837/WC500182235.pdf.
   Google Scholar
• Lawitz E, Gaultier I, Poordad F, et al. Initial antiviral activity of the HCV NS3 protease inhibitor ABT-450 when given with low dose ritonavir as 3-day monotherapy: preliminary results of study M11-602 in genotype-1 (GT1) HCV-infected treatment-naive subjects. Hepatology. 2010;52(Suppl 1):1202A.
   Google Scholar
• Poordad F, Agarwal K, Younes Z, et al. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis. 2015;60:608–610.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222–232.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Makara M, Akarca US, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology. 2015;149:971–980.
   PubMed Web of Science ®Google Scholar
• Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–2509.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama. 2015;313:1223–1231.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–2382.
   PubMed Web of Science ®Google Scholar
• Mantry PS, Brown RS, Enejosa J, et al. Ombitasvir/paritaprevir/r and dasabuvir with or without ribavirin for HCV patients with post-transplant recurrence (Abstract). Hepatology. 2015;62(Suppl 1):742A.
   Google Scholar
• Lalezari1 J, Sullivan JG, Rustgi V, et al. IFN-free 3 DAA regimen in HCV genotype 1-infected patients on methadone or buprenorphine (Poster 662LB). 21st Conference on Retroviruses and Opportunistic Infections; 2014 Mar 3–6; Boston, USA.
   Google Scholar
• Shafran S, Shaw D, Cohen E, et al. High rates of SVR in patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/r and sofosbuvir with or without ribavirin (Abstract). Hepatology. 2015;62(Suppl 1):LB16.
   Google Scholar
• Poordad F, Bennett M, Sepe TE, et al. Retreatment of HCV genotype 1 DAA-failures with ombitasvir/paritaprevir/r, dasabuvir, and sofosbuvir (Abstract). Hepatology. 2015;62(Suppl 1):LB20.
   Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–1614.
   PubMed Web of Science ®Google Scholar
• Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359–365.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al., PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–1992.
   PubMed Web of Science ®Google Scholar
• Conway B, Janczewska E, Luo Y, et al. MALACHITE-I: phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir ± ribavirin or telaprevir + peginterferon/ribavirin in treatment-naive adults with HCV genotype 1. J Hepatol. 2015;62(Suppl 2):653–654.
   Google Scholar
• Dore GJ, Conway B, Luo Y, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol. 2016;64:19–28.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Knysz B, Luo Y, et al. MALACHITE-II: phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir+ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with HCV genotype 1. J Hepatol. 2015;62(Suppl 2):656–657.
   Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
   PubMed Web of Science ®Google Scholar
• Poordad F, Feld JJ, Trinh R, et al. TURQUOISE-III: 12-week ribavirin-free regimen of ombitasvir/paritaprevir/r and dasabuvir for patients with HCV genotype 1b and cirrhosis (Abstract). Hepatology. 2015;62(Suppl1):724A.
   Google Scholar
• Mantry PS, Hanson J, Trinh R, et al. Ombitasvir/paritaprevir/r and dasabuvir with ribavirin for HCV genotype 1 patients with decompensated cirrhosis (Abstract). Hepatology. 2015;62(Suppl 1):568A.
   Google Scholar
• Pockros PJ, Reddy KR, Mantry PS, et al. RUBY-I: ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease (Abstract). Hepatology. 2015;62(Suppl 1):716A.
   Google Scholar
• Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study. J Hepatol. 2014;66(Suppl 1):L01.
   Google Scholar
• Asselah T, Hassanein TI, Qaqish RB, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (AGATE-I) (Abstract). Hepatology. 2015;62(Suppl 1):563A.
   Google Scholar
• Esmat G, Doss W, Qaqish RB, et al. Efficacy and safety of co-formulated ombitasvir/paritaprevir/ritonavir with ribavirin in adults with chronic HCV genotype 4 infection without cirrhosis and with compensated cirrhosis in Egypt (AGATE-II) (Abstract). Hepatology. 2015;62(Suppl 1):560A.
   Google Scholar
• Parruti G, Macedo G, Baumgarten A, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir +/- ribavirin in HCV genotype 1-infected patients with a history of bleeding disorders: Results from phase 3 trials (Abstract). Hepatology. 2015;62(Suppl 1):754A.
   Google Scholar
• Zeuzem S, Jacobson IM, Feld JJ, et al. Long-term efficacy of ombitasvir/paritaprevir/r and dasabuvir with or without ribavirin in HCV genotype 1-infected patients with or without cirrhosis (Abstract). Hepatology. 2015;62(Suppl 1):743A.
   Google Scholar
• Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. Efficacy and safety of paritaprevir/r/ombitasvir/dasabuvir +/- ribavirin in genotype 1 HCV infected patients treated in real life settings (AMBER study). J Viral Hepatitis. 2015;22(Suppl3):4.
   PubMed Web of Science ®Google Scholar
• Fried MW, Di Bisceglie AM, Vierling JM, et al. Safety of ABT-450/r/ombitasvir+ dasabuvir with or without ribavirin in HCV genotype 1-infected patients: results from phase 2 and phase 3 trials (Abstract). Hepatology. 2014;60(Suppl 1):1145A.
   Google Scholar
• Flamm S, Gane E, DuFour JF, et al. Safety of ABT-450/r/ombitasvir + dasabuvir with or without ribavirin in HCV genotype 1-infected patients ≥65 years of age: results from phase 2 and 3 trials (Abstract). Hepatology. 2014;60(Suppl 1):1157A.
   Google Scholar
• Conway B, Luo Y, Arama V, et al. Ombitasvir/paritaprevir/r and dasabuvir ± ribavirin is better tolerated than telaprevir + peginterferon/ribavirin with less frequent and less severe anemia in the MALACHITE-I and MALACHITE-II trials (Abstract). Hepatology. 2015;62(Suppl 1):782A.
   Google Scholar
• European Medicines Agency (EMA). Committee for medicinal products for human use (CHMP) assessment report. Viekirax. International non-proprietary name: ombitasvir/paritaprevir/ritonavir. Procedure No. EMEA/H/C/003839/0000. [ cited 2016 Mar 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003839/WC500183999.pdf.
   Google Scholar
• US Food and Drug Administration. FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. [ cited 2015 Dec 18]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm.
   Google Scholar
• US Food and Drug Administration. FDA approved drug products: Viekira Pak and Technivie. [ cited 2016 Mar 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207931Orig1s000lbl.pdf; http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf.
   Google Scholar
• Flisiak R, Jaroszewicz J, Janczewska E, et al. Predictors of decompensation during Ombitasvir/Paritaprevir/Ritonavir ±Dasabuvir ±Ribavirin treatment of genotype 1 and 4 HCV infected patients (real life AMBER study). J Hepatol. 2016;64(suppl):in press.
   Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
   PubMed Web of Science ®Google Scholar
• Krishnan P, Tripathi R, Schnell G, et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology. 2014;60:1134a–1135a.
   Web of Science ®Google Scholar
• Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir- and dasabuvir-based regimens. J Hepatol. 2015;62:S220–S220.
   Web of Science ®Google Scholar
• Wang C, Sun JH, OBoyle DR 2nd, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother. 2013;57:2054–2065.
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. Hepatology. 2015 Jul;63:199–236.
   Web of Science ®Google Scholar
• AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. [ cited 2016 Mar 6]. Available from: http://www.hcvguidelines.org/full-report/retreatment-box-summary-recommendations-patients-whom-previous-treatment-has-failed.
   Google Scholar